Status:
COMPLETED
CP-690-550 Ointment For Chronic Plaque Psoriasis
Lead Sponsor:
Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.
Eligibility Criteria
Inclusion
- Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of at least 6 months;
- A target plaque of at least 9 sq. cm.
Exclusion
- Demonstrates "rebound" or "flare" of chronic plaque psoriasis;
- Non plaque form of psoriasis;
- Currently have or history of psoriatic arthritis;
- Current drug induced psoriasis;
- Currently on systemic therapy or was on systemic therapy for psoriasis within the previous 6 months;
- Currently on phototherapy for psoriasis or was on phototherapy within the previous 3 months
Key Trial Info
Start Date :
February 16 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 29 2011
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT01246583
Start Date
February 16 2011
End Date
November 29 2011
Last Update
January 11 2021
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Horizon Research Group, Inc.
Mobile, Alabama, United States, 36608
2
Dermatology Research Associates
Los Angeles, California, United States, 90045
3
Expresscare Medical
Los Angeles, California, United States, 90045
4
Park Avenue Dermatology, PA
Orange Park, Florida, United States, 32073